{"id":"oral-escitalopram","safety":{"commonSideEffects":[{"rate":"15-20%","effect":"Nausea"},{"rate":"10-15%","effect":"Headache"},{"rate":"10-15%","effect":"Insomnia"},{"rate":"5-10%","effect":"Somnolence"},{"rate":"10-15%","effect":"Sexual dysfunction"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Dry mouth"},{"rate":"5-10%","effect":"Sweating"}]},"_chembl":{"chemblId":"CHEMBL1200322","moleculeType":"Small molecule","molecularWeight":"414.43"},"_dailymed":{"setId":"45ed4d16-6358-40a1-9352-319e58f55e5d","title":"ESCITALOPRAM ORAL SOLUTION (ESCITALOPRAM ORAL) SOLUTION [CHARTWELL GOVERNMENTAL & SPECIALTY RX, LLC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Escitalopram is the active S-enantiomer of citalopram and works as a selective serotonin reuptake inhibitor (SSRI). By blocking the serotonin transporter protein, it prevents the reabsorption of serotonin from the synaptic cleft back into the presynaptic neuron, thereby increasing serotonin concentration and enhancing neurotransmission. This mechanism is thought to improve mood and reduce anxiety symptoms in psychiatric disorders.","oneSentence":"Escitalopram selectively inhibits the reuptake of serotonin at the neuronal synapse, increasing serotonin availability in the brain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:24:40.387Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Major depressive disorder"},{"name":"Generalized anxiety disorder"},{"name":"Panic disorder"},{"name":"Social anxiety disorder"},{"name":"Obsessive-compulsive disorder"}]},"trialDetails":[{"nctId":"NCT07478796","phase":"PHASE4","title":"TDM-Guided Treatment With SSRIs in Hospitalized Adults and Children","status":"RECRUITING","sponsor":"Poznan University of Medical Sciences","startDate":"2025-04-03","conditions":"Depression - Major Depressive Disorder, Depressive Episodes","enrollment":180},{"nctId":"NCT07480525","phase":"NA","title":"Efficacy and Mechanisms of Escitalopram in Drug-Naïve First-Episode Major Depressive Disorder","status":"NOT_YET_RECRUITING","sponsor":"Peking University","startDate":"2026-03-20","conditions":"Depression - Major Depressive Disorder","enrollment":200},{"nctId":"NCT06049797","phase":"","title":"A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweats","status":"ACTIVE_NOT_RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2023-11-15","conditions":"Hot Flashes","enrollment":999},{"nctId":"NCT06826326","phase":"PHASE2","title":"Neuroimaging of Escitalopram in Autism Spectrum Disorder","status":"ENROLLING_BY_INVITATION","sponsor":"Kathryn Unruh","startDate":"2025-04-28","conditions":"Autism Spectrum Disorder","enrollment":5},{"nctId":"NCT07399795","phase":"","title":"Citalopram and the Risk of Serious Adverse Events","status":"COMPLETED","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2008-01-01","conditions":"Chronic Kidney Disease (CKD), Elderly, Outpatient","enrollment":7110},{"nctId":"NCT07274241","phase":"","title":"Escitalopram and the Risk of Serious Adverse Events","status":"COMPLETED","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2008-01-01","conditions":"Chronic Kidney Disease (CKD), Elderly, Outpatient","enrollment":12145},{"nctId":"NCT06216535","phase":"PHASE2","title":"Escitalopram in Asthma Patients With Frequent Exacerbation","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2025-05-19","conditions":"Asthma","enrollment":105},{"nctId":"NCT06937476","phase":"NA","title":"Neurobiological Mechanisms of Pathological Rumination and Effects of Aripiprazole","status":"RECRUITING","sponsor":"Central South University","startDate":"2025-05-08","conditions":"Major Depressive Disorder (MDD), Rumination","enrollment":108},{"nctId":"NCT06705478","phase":"PHASE2","title":"Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV","status":"NOT_YET_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2026-02-15","conditions":"Major Depressive Disorder, Mild Neurocognitive Disorder, HIV","enrollment":186},{"nctId":"NCT07331987","phase":"NA","title":"Efficacy and Safety of Probiotics for Anxiety Depression","status":"NOT_YET_RECRUITING","sponsor":"Moon (Guangzhou) Biotechnology Co., Ltd.","startDate":"2026-03-01","conditions":"Anxiety Depression","enrollment":60},{"nctId":"NCT06965569","phase":"PHASE1","title":"Multiple Ascending Dose Phase 1 Study of ALA-3000","status":"COMPLETED","sponsor":"Alar Pharmaceuticals Inc.","startDate":"2025-04-21","conditions":"Treatment Resistant Depression","enrollment":37},{"nctId":"NCT06433635","phase":"PHASE4","title":"Sequential Multiple Assignment Randomized Trial for Bipolar Depression","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2024-10-01","conditions":"Bipolar I Disorder, Depression","enrollment":2726},{"nctId":"NCT06692361","phase":"NA","title":"Assessment of the Efficacy and Safety of Fecal Microbiota Transplantation (FMT) in Patients With Major Depressive Disorder","status":"RECRUITING","sponsor":"Gang Wang","startDate":"2025-01-01","conditions":"Major Depressive Disorder (MDD), Depression - Major Depressive Disorder","enrollment":214},{"nctId":"NCT06746441","phase":"PHASE2","title":"Effect of Psilocybin Only and Psilocybin Assisted Cognitive Behavioral Therapy in the Management of Major Depressive Disorder and Associated Metabolic, Immune, Inflammatory, Neuroplasticity and Electrical Activity Markers","status":"COMPLETED","sponsor":"Khyber Medical University Peshawar","startDate":"2024-12-01","conditions":"Major Depressive Disorder","enrollment":60},{"nctId":"NCT07120880","phase":"PHASE3","title":"Efficacy of Chronotherapeutic Combination for Major Depressive Episode With Insomnia","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2025-09","conditions":"Major Depressive Disorder (MDD) With Insomnia","enrollment":184},{"nctId":"NCT07113145","phase":"PHASE4","title":"Comparative Evaluation of Safety and Efficacy of Dapoxetine, Silodosin, and Citalopram in the Management of Premature Ejaculation","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2024-06-01","conditions":"Premature (Early) Ejaculation","enrollment":450},{"nctId":"NCT03527043","phase":"PHASE2","title":"Impact of Escitalopram on Sperm DNA Fragmentation","status":"TERMINATED","sponsor":"Weill Medical College of Cornell University","startDate":"2017-10-01","conditions":"Sperm DNA Fragmentation, Infertility, Male","enrollment":75},{"nctId":"NCT06192589","phase":"PHASE1","title":"Clinical Study to Evaluate Cannabidiol Liver Enzyme Elevations and Drug Interactions","status":"COMPLETED","sponsor":"Food and Drug Administration (FDA)","startDate":"2024-02-08","conditions":"Cannabidiol, Drug Induced Liver Injury, Drug Interaction","enrollment":241},{"nctId":"NCT07077291","phase":"NA","title":"MBCT and Escitalopram for Treatment-Resistant Depression in Older Adults","status":"COMPLETED","sponsor":"Yun Zhang","startDate":"2020-02-01","conditions":"Treatment-resistant Depression (TRD)","enrollment":230},{"nctId":"NCT04344678","phase":"NA","title":"The Phosphodiesterase 5 Inhibitor Sildenafil as an Adjunct to Antidepressants in Major Depressive Disorder Patients","status":"WITHDRAWN","sponsor":"Sadat City University","startDate":"2020-01-01","conditions":"Major Depressive Disorder","enrollment":""},{"nctId":"NCT03728673","phase":"PHASE2","title":"A Study Utilizing Escitalopram in Glioma Patients","status":"RECRUITING","sponsor":"University of Nebraska","startDate":"2019-03-06","conditions":"Glioma of Brain, Glioma","enrollment":20},{"nctId":"NCT03887624","phase":"EARLY_PHASE1","title":"Investigate the Clinical Responses of Ethosuximide in Patients With Treatment-Resistant Depression.","status":"COMPLETED","sponsor":"Zhejiang University","startDate":"2019-05-21","conditions":"Depressive Disorder, Treatment-Resistant","enrollment":16},{"nctId":"NCT06476509","phase":"PHASE1","title":"A Study to Assess Serotonin Transporter Occupancy of Healthy Adults Using 11C-DASB PET","status":"COMPLETED","sponsor":"Vigonvita Life Sciences","startDate":"2024-05-30","conditions":"Major Depressive Disorder","enrollment":20},{"nctId":"NCT04973930","phase":"PHASE3","title":"Feasibility Trial of Tele-IPT and Tele-Pharmacotherapy for Patients With Depression and Non-Metastatic Breast Cancer","status":"SUSPENDED","sponsor":"New York State Psychiatric Institute","startDate":"2022-03-01","conditions":"Major Depressive Disorder, Breast Cancer, Venlafaxine","enrollment":20},{"nctId":"NCT02417064","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-08-10","conditions":"Treatment-resistant Depression","enrollment":346},{"nctId":"NCT03434041","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-05-25","conditions":"Depressive Disorder, Treatment-Resistant","enrollment":252},{"nctId":"NCT02493868","phase":"PHASE3","title":"A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-10-01","conditions":"Depressive Disorder, Treatment-Resistant","enrollment":719},{"nctId":"NCT02418585","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-08-07","conditions":"Treatment-resistant Depression","enrollment":236},{"nctId":"NCT02497287","phase":"PHASE3","title":"A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-09-30","conditions":"Treatment-resistant Depression","enrollment":802},{"nctId":"NCT02422186","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-08-20","conditions":"Depressive Disorder, Treatment-Resistant","enrollment":139},{"nctId":"NCT03321526","phase":"PHASE2","title":"A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-12-12","conditions":"Depressive Disorder, Major","enrollment":107},{"nctId":"NCT04951609","phase":"PHASE1","title":"A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adolescents With Major Depressive Disorder Who Have an Inadequate Response to Selective Serotonin Reuptake Inhibitor (SSRI) and Psychotherapy","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-09-02","conditions":"Depressive Disorder, Major","enrollment":31},{"nctId":"NCT03852160","phase":"PHASE3","title":"A Study of Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New Standard-of-care Oral Antidepressant in Adult and Elderly Participants With Treatment-resistant Depression","status":"WITHDRAWN","sponsor":"Janssen-Cilag International NV","startDate":"2019-12-01","conditions":"Depressive Disorder, Treatment-Resistant","enrollment":""},{"nctId":"NCT06828887","phase":"PHASE2","title":"Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LV232 Capsules in the Treatment of MDD","status":"RECRUITING","sponsor":"Vigonvita Life Sciences","startDate":"2025-04-03","conditions":"MDD","enrollment":400},{"nctId":"NCT03920410","phase":"NA","title":"Effect of Serotonergic Stimulation on the Gut-brain Axis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Örebro University, Sweden","startDate":"2019-04-24","conditions":"Healthy, Irritable Bowel Syndrome","enrollment":58},{"nctId":"NCT03128021","phase":"PHASE4","title":"Neural Mechanisms of Monoaminergic Engagement in Late-life Depression Treatment Response (NEMO)","status":"COMPLETED","sponsor":"Howard Aizenstein","startDate":"2017-05-24","conditions":"Major Depressive Disorder","enrollment":57},{"nctId":"NCT06412315","phase":"NA","title":"7T Amygdala and Citalopram Study","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2025-02-13","conditions":"Emotional Processing, Cognition, Mood Disorders","enrollment":50},{"nctId":"NCT04336228","phase":"PHASE4","title":"The Role of Serotonin in Compulsive Behavior in Humans: Underlying Brain Mechanisms","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2020-04-01","conditions":"Obsessive-Compulsive Disorder/High Compulsive Individuals, Healthy Individuals","enrollment":46},{"nctId":"NCT04301271","phase":"PHASE2","title":"Simvastatin add-on Treatment to Standard Antidepressant Therapy in Patients With Comorbid Obesity and Major Depression","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2020-08-13","conditions":"Depressive Disorder, Major, Obesity","enrollment":161},{"nctId":"NCT06680531","phase":"PHASE1","title":"A Clinical Study to Evaluate the Drug Interaction Between YZJ-1139 Tablets and Escitalopram Oxalate Tablets","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Haiyan Pharmaceutical Technology Co., Ltd.","startDate":"2024-08-31","conditions":"Insomnia, Central Nervous System","enrollment":24},{"nctId":"NCT05599126","phase":"PHASE4","title":"A Study of Mianserin in Combination With SSRIs in Depression With Sleep Problems","status":"RECRUITING","sponsor":"Zhenghui YI","startDate":"2024-07-01","conditions":"Depression","enrollment":300},{"nctId":"NCT03909217","phase":"PHASE2, PHASE3","title":"Treating Depression With Transcutaneous Electrical Cranial-auricular Acupoint Stimulation (TECAS).","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2019-07-29","conditions":"Mild-to-moderate Depression","enrollment":470},{"nctId":"NCT02620150","phase":"PHASE4","title":"SSRI Effects on Depression and Immunity in HIV/AIDS","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2017-02-16","conditions":"Depression, HIV, AIDS","enrollment":108},{"nctId":"NCT00648570","phase":"PHASE1","title":"Fasting Study of Escitalopram Oxalate Tablets 20 mg and Lexapro® Tablets 20 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2004-08","conditions":"Healthy","enrollment":37},{"nctId":"NCT06358014","phase":"NA","title":"Assessment of the Improvement in Cognitive Levels of Postmenopausal Depression Patients by Estrogen","status":"RECRUITING","sponsor":"Xiao Wang","startDate":"2023-05-12","conditions":"Postmenopausal Depression, Estrogen","enrollment":40},{"nctId":"NCT06325605","phase":"NA","title":"Efficacy and Safety of Bifidobacterium Combined With High-frequency Transcranial Magnetic Stimulation in the Treatment of Adolescent Depression","status":"COMPLETED","sponsor":"Zhen-Hong Hu","startDate":"2022-03-01","conditions":"Adolescent Depression","enrollment":100},{"nctId":"NCT05720637","phase":"NA","title":"The Efficacy and Cerebral Mechanism of Intradermal Acupuncture for Major Depressive Disorder","status":"COMPLETED","sponsor":"Xiaomei Shao","startDate":"2022-11-01","conditions":"Major Depressive Disorder","enrollment":120},{"nctId":"NCT04476030","phase":"PHASE3","title":"A Comparative Study of Sage-217 Plus an Antidepressant (ADT) Versus Placebo Plus an ADT in Adults With Major Depressive Disorder","status":"COMPLETED","sponsor":"Biogen","startDate":"2020-11-09","conditions":"Depressive Disorder, Major","enrollment":440},{"nctId":"NCT05818735","phase":"NA","title":"Effect of Electroacupuncture on Treating the First-episode Depression","status":"RECRUITING","sponsor":"Shanghai Municipal Hospital of Traditional Chinese Medicine","startDate":"2023-12-01","conditions":"Depression","enrollment":204},{"nctId":"NCT03538691","phase":"PHASE3","title":"A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2018-07-13","conditions":"Major Depressive Disorder","enrollment":1149},{"nctId":"NCT05931965","phase":"NA","title":"Combination Therapy of Different Antidepressants With Dietary Supplements","status":"COMPLETED","sponsor":"Riphah International University","startDate":"2022-10-05","conditions":"Depression","enrollment":88},{"nctId":"NCT06025474","phase":"PHASE3","title":"Comparison of Vortioxetine Versus Other Antidepressants With Pregabalin Augmentation in Burning Mouth Syndrome","status":"UNKNOWN","sponsor":"Federico II University","startDate":"2023-01-01","conditions":"Burning Mouth Syndrome","enrollment":203},{"nctId":"NCT06017037","phase":"PHASE1, PHASE2","title":"REward Processing And Citalopram Study","status":"UNKNOWN","sponsor":"University of Oxford","startDate":"2023-05-19","conditions":"Anhedonia","enrollment":40},{"nctId":"NCT00876226","phase":"NA","title":"Pharmacokinetics of Citalopram in Patients With Short Bowel Syndrome","status":"WITHDRAWN","sponsor":"University of Nebraska","startDate":"2010-05-01","conditions":"Short Bowel Syndrome","enrollment":""},{"nctId":"NCT04763135","phase":"PHASE3","title":"Mirtazapine in Cancer-related Poly-symptomatology","status":"TERMINATED","sponsor":"Hospices Civils de Lyon","startDate":"2021-12-15","conditions":"Cancer, Neoplasms, Neoplasm Metastasis","enrollment":1},{"nctId":"NCT03652870","phase":"PHASE3","title":"Antidepressants Trial in Parkinson's Disease","status":"COMPLETED","sponsor":"University College, London","startDate":"2021-03-05","conditions":"Depression, Parkinson Disease","enrollment":52},{"nctId":"NCT05832619","phase":"NA","title":"Intradermal Acupuncture Versus Sham Acupuncture and SSRI for Treating Adolescents With Major Depressive Disorder","status":"UNKNOWN","sponsor":"Xiaomei Shao","startDate":"2022-11-01","conditions":"Major Depressive Disorder","enrollment":120},{"nctId":"NCT05480878","phase":"PHASE3","title":"Role of Nitazoxanide and Escitalopram in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Tanta University","startDate":"2022-12-02","conditions":"Rheumatoid Arthritis","enrollment":90},{"nctId":"NCT05795283","phase":"","title":"Potential Predictive Biological Markers of Major Depression Response to Citalopram Therapy in Anorexia Nervosa.","status":"UNKNOWN","sponsor":"Istituto Auxologico Italiano","startDate":"2022-08-01","conditions":"Anorexia Nervosa","enrollment":123},{"nctId":"NCT05737511","phase":"PHASE4","title":"Efficacy of Hydroxyzine for Patients With Panic Disorder","status":"NOT_YET_RECRUITING","sponsor":"Sultan Qaboos University","startDate":"2023-12-30","conditions":"Panic Disorder","enrollment":80},{"nctId":"NCT03924323","phase":"PHASE4","title":"A Study of Escitalopram in the Treatment of Children and Adolescents With Generalized Anxiety Disorder","status":"COMPLETED","sponsor":"AbbVie","startDate":"2019-05-30","conditions":"Anxiety Disorders,Generalized Anxiety Disorder","enrollment":273},{"nctId":"NCT03516604","phase":"PHASE1","title":"PF-04995274 and Emotional Processing in Un-medicated Depression","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2018-05-16","conditions":"Depression, Unipolar","enrollment":90},{"nctId":"NCT05605002","phase":"NA","title":"Efficacy and Safety of Intradermal Acupuncture for Major Depressive Disorder","status":"UNKNOWN","sponsor":"Xiaomei Shao","startDate":"2022-01-01","conditions":"Major Depressive Disorder","enrollment":90},{"nctId":"NCT04069819","phase":"NA","title":"The Phosphodiesterase-3 Inhibitor Cilostazol as an Adjunctive to Antidepressants in Patients With Major Depressive Disorder.","status":"COMPLETED","sponsor":"Sadat City University","startDate":"2019-08-01","conditions":"Major Depressive Disorder","enrollment":80},{"nctId":"NCT05147077","phase":"NA","title":"Integrated Rehabilitation in Treating Post-stroke Anxiety","status":"UNKNOWN","sponsor":"The Third Affiliated hospital of Zhejiang Chinese Medical University","startDate":"2022-01-24","conditions":"Post-stroke, Anxiety","enrollment":188},{"nctId":"NCT04145076","phase":"NA","title":"Brain Response to Serotonergic Medications in ASD","status":"UNKNOWN","sponsor":"King's College London","startDate":"2014-12-15","conditions":"Autism Spectrum Disorder","enrollment":100},{"nctId":"NCT04965272","phase":"PHASE2","title":"A Study To Assess Adverse Events and Change in Disease Activity With Oral Cariprazine When Added to Antidepressant Therapies (ADTs) Compared to Placebo in Adult Participants With Generalized Anxiety Disorder (GAD) Who Have Had an Inadequate Response to ADTs Alone","status":"WITHDRAWN","sponsor":"AbbVie","startDate":"2021-08-18","conditions":"Generalized Anxiety Disorder","enrollment":""},{"nctId":"NCT01312922","phase":"PHASE3","title":"Pipamperone/Citalopram (PNB01) Versus Citalopram (CIT) and Versus Pipamperone (PIP) in Major Depressive Disorder (MDD)","status":"COMPLETED","sponsor":"PharmaNeuroBoost N.V.","startDate":"2011-09","conditions":"Major Depressive Disorder","enrollment":555},{"nctId":"NCT01123707","phase":"PHASE3","title":"To Assess the Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)","status":"TERMINATED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2010-11-18","conditions":"Major Depressive Disorder (MDD)","enrollment":173},{"nctId":"NCT01111565","phase":"PHASE3","title":"Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)","status":"TERMINATED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2010-10-04","conditions":"Major Depressive Disorder (MDD)","enrollment":137},{"nctId":"NCT05148169","phase":"PHASE4","title":"A Pilot Study on Effect of add-on Sulforaphane to SSRIs and Application of Niacin Skin Flush Response Test in Major Depressive Disorder","status":"UNKNOWN","sponsor":"Shanghai Mental Health Center","startDate":"2020-01-01","conditions":"Major Depressive Disorder","enrollment":150},{"nctId":"NCT05145270","phase":"PHASE4","title":"A Comparative Study on Efficacy and Safety of add-on Sulforaphane or rTMS to Escitalopram for Major Depressive Disorder With Poor Response to Initial Treatment","status":"UNKNOWN","sponsor":"Shanghai Mental Health Center","startDate":"2019-11-30","conditions":"Major Depressive Disorder","enrollment":180},{"nctId":"NCT01111552","phase":"PHASE3","title":"Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)","status":"TERMINATED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2010-07-29","conditions":"Major Depressive Disorder (MDD)","enrollment":237},{"nctId":"NCT01111539","phase":"PHASE3","title":"Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)","status":"TERMINATED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2010-07-13","conditions":"Major Depressive Disorder (MDD)","enrollment":211},{"nctId":"NCT03388164","phase":"PHASE2","title":"Adherence to Antidepressant Treatment in Subjects With Depression","status":"TERMINATED","sponsor":"Laureate Institute for Brain Research, Inc.","startDate":"2018-01-01","conditions":"Depression","enrollment":23},{"nctId":"NCT05041582","phase":"PHASE3","title":"SSRIs and TDCS Enhance Post-stroke Motor Recovery","status":"UNKNOWN","sponsor":"Chih-Wei Tang","startDate":"2021-09-01","conditions":"Stroke, Motor","enrollment":80},{"nctId":"NCT01436175","phase":"PHASE3","title":"SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension Study","status":"TERMINATED","sponsor":"Shire","startDate":"2012-02-27","conditions":"Major Depressive Disorder","enrollment":1570},{"nctId":"NCT00905424","phase":"PHASE2","title":"Exploratory Study of SPD489 in Adults With Major Depressive Disorder (MDD) as Augmentation Therapy to an Antidepressant","status":"COMPLETED","sponsor":"Shire","startDate":"2009-07-30","conditions":"Major Depressive Disorder","enrollment":246},{"nctId":"NCT01436162","phase":"PHASE3","title":"Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder","status":"COMPLETED","sponsor":"Shire","startDate":"2011-10-19","conditions":"Major Depressive Disorder","enrollment":1105},{"nctId":"NCT01436149","phase":"PHASE3","title":"Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder","status":"COMPLETED","sponsor":"Shire","startDate":"2011-10-27","conditions":"Major Depressive Disorder","enrollment":1262},{"nctId":"NCT04097288","phase":"PHASE1","title":"Effects of Single Dose Citalopram and Reboxetine on Urethral and Anal Closure Function on Healthy Female Subjects","status":"COMPLETED","sponsor":"University Hospital Bispebjerg and Frederiksberg","startDate":"2019-09-17","conditions":"Stress Urinary Incontinence, Fecal Incontinence","enrollment":24},{"nctId":"NCT03912974","phase":"PHASE1","title":"Effects of SERT Inhibition on the Subjective Response to Psilocybin in Healthy Subjects","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2019-07-04","conditions":"Healthy","enrollment":27},{"nctId":"NCT02818751","phase":"NA","title":"Neurofunctional Predictors of Escitalopram Treatment Response in Adolescents With Anxiety","status":"COMPLETED","sponsor":"University of Cincinnati","startDate":"2015-05","conditions":"Anxiety","enrollment":84},{"nctId":"NCT04590612","phase":"NA","title":"Improving Quality of Life in Early Parkinson's Disease","status":"UNKNOWN","sponsor":"Western University, Canada","startDate":"2021-01","conditions":"Parkinson Disease, Depression","enrollment":30},{"nctId":"NCT03464383","phase":"PHASE4","title":"Anxiety and Depression in Epilepsy: A Treatment Study","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2018-05-07","conditions":"Anxiety, Depression, Epilepsy","enrollment":69},{"nctId":"NCT00584571","phase":"PHASE2","title":"SAT vs Escitalopram for Rectal Hypersensitivity","status":"COMPLETED","sponsor":"Augusta University","startDate":"2007-12","conditions":"Rectal Hypersensitivity, Irritable Bowel Syndrome-Constipation","enrollment":55},{"nctId":"NCT01931202","phase":"NA","title":"Mechanisms of Antidepressant Non-Response in Late-Life Depression","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2014-02-19","conditions":"Major Depressive Disorder","enrollment":138},{"nctId":"NCT03274817","phase":"PHASE1","title":"A Proof of Concept Study of the Prevention of Mild Cognitive Impairment and Eventual Alzheimer's Disease Using F18 Flutemetamol","status":"TERMINATED","sponsor":"NYU Langone Health","startDate":"2009-06-18","conditions":"Alzheimer Disease","enrollment":5},{"nctId":"NCT01041274","phase":"PHASE4","title":"DECIFER: Depression and Citalopram In First Episode Recovery","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2010-01","conditions":"Schizophrenia, Schizophreniform Disorder","enrollment":95},{"nctId":"NCT03499171","phase":"PHASE4","title":"Citalopram for Reflux Hypersensitivity and Functional Heartburn","status":"UNKNOWN","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2019-05-27","conditions":"GERD","enrollment":100},{"nctId":"NCT04169230","phase":"NA","title":"Citalopram and Self Emotional Processing","status":"UNKNOWN","sponsor":"University of Oxford","startDate":"2019-10-11","conditions":"Molecular Mechanisms of Pharmacological Action, Depression, Depressive Disorder","enrollment":44},{"nctId":"NCT04161209","phase":"NA","title":"Citalopram and Stress Reactivity","status":"UNKNOWN","sponsor":"University of Oxford","startDate":"2019-10-11","conditions":"Depression, Depressive Disorder, Mental Disorder","enrollment":40},{"nctId":"NCT03907215","phase":"PHASE1","title":"A Clinical Study to Examine the Drug-drug Interactions Between ACT-541468 and Citalopram in Healthy Male and Female Subjects","status":"COMPLETED","sponsor":"Idorsia Pharmaceuticals Ltd.","startDate":"2019-04-09","conditions":"Healthy","enrollment":24},{"nctId":"NCT00703742","phase":"NA","title":"A Neuroimaging and Epigenetic Investigation of Antidepressants in Depression","status":"COMPLETED","sponsor":"Kunming Medical University","startDate":"2008-06","conditions":"Depression, Depression Secondary to Other Disease","enrollment":200},{"nctId":"NCT03522987","phase":"PHASE4","title":"Anxiety and Depression in Epilepsy: A Pilot Treatment Study","status":"WITHDRAWN","sponsor":"Wake Forest University Health Sciences","startDate":"2018-05","conditions":"Anxiety, Depression, Epilepsy","enrollment":""},{"nctId":"NCT01715805","phase":"PHASE3","title":"Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2012-11-15","conditions":"Major Depressive Disorder","enrollment":1022},{"nctId":"NCT01838876","phase":"PHASE3","title":"Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy in Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2013-04-29","conditions":"Major Depressive Disorder","enrollment":442},{"nctId":"NCT04037111","phase":"NA","title":"Clinical Study of Escitalopram Oxalate Combined With taVNS in Depression and Concomitant Inflammatory Symptoms","status":"UNKNOWN","sponsor":"Xijing Hospital","startDate":"2019-07-23","conditions":"Major Depressive Disorder, Rheumatoid Arthritis","enrollment":90},{"nctId":"NCT03010761","phase":"PHASE2","title":"Establishment of Cessation Therapy by Clinical Trials for Subjects With Betel-quid Dependence and Oral Pre-cancer","status":"TERMINATED","sponsor":"China Medical University Hospital","startDate":"2016-01-14","conditions":"Addiction","enrollment":90},{"nctId":"NCT03607331","phase":"EARLY_PHASE1","title":"Auricular Concha Electro-acupuncture for the Treatment of Depression","status":"UNKNOWN","sponsor":"China Academy of Chinese Medical Sciences","startDate":"2018-09-17","conditions":"Depression, Depressive Symptom, Depressive Disorder","enrollment":106}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":27,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"oral escitalopram","genericName":"oral escitalopram","companyName":"NYU Langone Health","companyId":"nyu-langone-health","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Escitalopram selectively inhibits the reuptake of serotonin at the neuronal synapse, increasing serotonin availability in the brain. Used for Major depressive disorder, Generalized anxiety disorder, Panic disorder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}